The Italian subsidiary, Takeda Italy SpA, with a product portfolio in which is enriched through research and development carried out in Japan and beyond, and a modern manufacturing plant in Cerano (NO), ranks among the largest companies in the domestic pharmaceutical market.
Takeda is a company led by an innovative medical research aimed at improving the lives and health of patients, through services and products of superior quality, highly competitive in the development, production and marketing of drugs on the therapeutic areas of greatest impact with social skills and performance excellence within the Group.
To achieve its mission, the company puts the Takeda-ism in the center of the system, ie, the range of values unchanged sign of the unity of the Takeda Group which aims to improve health of patients in the world through cutting-edge innovation in medicine.
Contact
Registered Office :
Via Elio Vittorini, 129
00144 Rome
tel. +39 06 50260.1
Fax +39 06 5011709
Web: takeda.it
Chris Juliam, Managing Director for Takeda Italy, shares the strategy the company is pursuing in the country, the effects market-access issues are having on innovators and patients, and what new…
Takeda has more than 25 years of history in Italy and reached the 20th position in the Italian market- a striking performance in a context when it is still rare…
Ahead of the imminent acquisition of Baxalta by Shire, country managing director Italy Fabio Andreola shares his perspective on the rare-disease environment in Italy and how Baxalta will contribute to…
Maurizio Marchesini, CEO of Marchesini Group, discusses the challenges of competing in a very dynamic packaging machinery industry, where their business is differentiated through flexibility and integral service offerings. Further,…
Riccardo Palmisano, CEO of MolMed, discusses the latest developments for their late-stage clinical development products, and comments on the recent approval of Strimvelis, a gene therapy developed by GSK and…
Paolo Marcucci, President and CEO of Kedrion Biopharma, talks about the factors behind the company’s incredible growth and its commitment to doubling exports to the US. Furthermore, he talks about…
Shire Italy’s Francesco Scopesi discusses innovative medicine, rare diseases, growth drivers, global strategy, and the new trend of home care. Shire is today one of the leading biotechs delivering innovative…
Long renowned for dancing to a different tune, Italy’s eccentric, but more often than not, enlightened and high performance pharma, healthcare and life sciences community may at last be about…
Doppel has been selected as the nucleus for significant investments in the CDMO industry by PE firm Trilantic Capital Partners, according to recently hired CEO Giuseppe Cassisi, who shares the organization’s plans to…
Sergio Liberatore discusses IMS Health Italy’s evolution after the acquisition of Cegedim’s CRM and strategic data businesses and how IMS is paving the way for pharma companies to become more patient-centric. When we last…
Abramo Brandi, Octapharma Italy’s MD, discusses the challenges of the tender system in Italy and how he has grown the company year-on-year in the midst of a global economic crisis.…
Mario Marazziti, President of the Italian XII Social Affairs Commission, discusses new legislation relating to clinical risk, the effects of the 2014 Pact for Health, and the efficiency of Italian…
Luigi Boggio, President of Assobiomedica, the association representing the medtech industry, and MD of B. Braun Italy, calls on the Italian government to implement a national system that measures the…
GE Healthcare Italy’s Marco Campione discusses patient access to innovation, synergies between pharma and medtech in companion diagnostics, and partnering with the Italian healthcare system. You have been working at…
See our Cookie Privacy Policy Here
